Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Quest Will Acquire Genome Pioneer Celera
by Rick Mullin
March 28, 2011
| A version of this story appeared in
Volume 89, Issue 13
Quest Diagnostics has agreed to acquire Celera, a genetic diagnostics firm, in a stock deal valued at $344 million. Quest will gain access to Celera’s proprietary genetic tests and its pipeline of biomarkers. The company will also get a cardiovascular testing technology developed by Berkeley HeartLab, a division of Celera. “Our discovery and validation of new biomarkers have exceeded our capacity to commercialize them,” says Celera CEO Kathy Ordoñez in explaining the sale to the larger Quest. Celera was formed in 1998 to sequence the human genome. J. Craig Venter was the firm’s first president.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter